Tirzepatide vs Alternatives: Which Wins for Weight Loss

By Victor Björk

Tirzepatide is the most effective approved pharmacotherapy for obesity that currently exists, and if your primary goal is maximum fat loss without established cardiovascular disease, the trial data make the choice straightforward. The caveat is real, though: “most effective” and “best for every patient” are not the same sentence, and conflating them is exactly the kind of reasoning that gets people into trouble with high-stakes prescribing decisions.

The Verdict Up Front

In SURMOUNT-1, tirzepatide at 15 mg produced mean body weight reductions of 20.9% over 72 weeks. A 2023 meta-analysis of 10 RCTs covering 9,873 patients confirmed that tirzepatide produced significantly greater weight loss versus placebo by 9.81 kg (95% CI: -12.09, -7.52), and outperformed GLP-1 receptor agonists as a class by an additional 1.05 kg, with all three doses showing significant reductions. [1] Nothing else approved for obesity comes close on a per-trial basis.

Semaglutide 2.4 mg is the more mature agent on cardiovascular outcomes. A 2026 meta-analysis found that semaglutide reduced heart failure events by 16% overall (RR 0.84) and by 31% in patients without baseline heart failure (RR 0.69) across populations with type 2 diabetes and obesity. [2] Tirzepatide does not yet have a published cardiovascular outcomes trial in obesity, and that gap matters enormously for the right patient.

The short version: Tirzepatide wins on weight loss. Semaglutide wins on cardiovascular evidence. Liraglutide is a distant third on both counts but retains a specific, narrow use case.

What Each Drug Actually Does

The mechanism distinction here is not academic. Tirzepatide is a single synthetic peptide that acts simultaneously at both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, a dual agonism that is mechanistically distinct from every approved GLP-1 monotherapy. A 2025 review in Molecular Metabolism confirmed that GIPR signal modification represents a genuinely distinct pharmacotherapeutic approach, not simply a quantitative upgrade on GLP-1 agonism. [3]

Why does the GIP arm matter? A 2024 review in Cell covering multi-receptor GLP-1-based drugs reports that GIP co-agonism contributes complementary pharmacology, including beneficial effects on adipose tissue insulin sensitivity, glycemia, and fatty liver, though the precise weight attributed to each receptor arm in producing weight loss remains actively debated. [4] We know the combination works better than GLP-1 alone; clean mechanistic attribution is still outstanding.

Semaglutide 2.4 mg acts exclusively at the GLP-1 receptor, suppressing appetite and slowing gastric emptying. A 2024 systematic review of human pharmacokinetic data confirms a long half-life supporting once-weekly subcutaneous dosing with predictable profiles across healthy and diseased populations. [5] The receptor biology is well understood, the clinical experience is now several years deep, and the cardiovascular outcomes data exist.

Liraglutide 3.0 mg shares the GLP-1 receptor mechanism but carries a half-life of roughly 13 hours, requiring daily rather than weekly injection. A 2026 network meta-analysis in adults with overweight or obesity without diabetes found liraglutide 3.0 mg associated with a mean body weight reduction of only 6.4% versus placebo, well below both semaglutide and tirzepatide. [6] Lower efficacy ceiling plus daily injection burden makes liraglutide a third-line agent for most patients.

Head-to-Head: Efficacy

The numbers across phase 3 trials tell a clear story, with one important caveat about cross-trial comparisons.

• Tirzepatide (SURMOUNT-1): 10 mg and 15 mg produced mean weight reductions of 19.5% and 20.9% respectively versus 3.1% for placebo at 72 weeks in adults without diabetes. [1]

• Semaglutide 2.4 mg (STEP-1): A 2026 network meta-analysis places the mean body weight reduction at 11.45% versus placebo in adults without diabetes. [6]

• Liraglutide 3.0 mg (SCALE): Mean weight reduction of approximately 6.4% versus placebo in comparable populations, roughly one-third the magnitude of tirzepatide 15 mg. [6]

Treating these as a direct three-way comparison is tempting but premature: no published head-to-head RCT has randomized tirzepatide against semaglutide 2.4 mg for obesity. The SURPASS-2 trial compared them in type 2 diabetes, but used semaglutide 1.0 mg, the diabetes dose, not the 2.4 mg obesity dose. A 2023 systematic review acknowledged this limitation explicitly, noting that cross-trial inference between tirzepatide and GLP-1 receptor agonists is constrained by differences in trial populations, durations, and comparator doses. [1] The weight loss gap between tirzepatide and semaglutide 2.4 mg is likely real, but its precise magnitude awaits a properly powered head-to-head trial.

A useful analogy: this situation resembles the early years of comparing insulin analogues, where glargine and detemir were each tested against NPH in separate trials before anyone ran them head-to-head. The cross-trial numbers suggested glargine was superior; the head-to-head data were more equivocal. The same caution applies here.

Head-to-Head: Safety

Both agents produce substantial gastrointestinal side effects, and the framing that tirzepatide is “better tolerated” than semaglutide is not well supported by the data.

Tirzepatide GI burden: A 2024 meta-analysis of seven RCTs covering 4,795 individuals found gastrointestinal side effects were the most frequently reported adverse events across all three tirzepatide doses (5, 10, and 15 mg), described as generally mild-to-moderate and transient. [7] SURMOUNT-1 reported GI adverse events in 80.5% of tirzepatide-treated participants, with 4.3% discontinuing due to GI events at the 15 mg dose.

Semaglutide GI burden: A 2026 phase 2 randomized trial of bimagrumab plus semaglutide confirmed nausea, diarrhea, constipation, and fatigue as consistent features of semaglutide 2.4 mg’s safety profile. [8] STEP-1 reported nausea in 44.2% of semaglutide participants versus 16.0% for placebo, with a 7.0% discontinuation rate due to adverse events in the semaglutide group.

The thyroid question: Tirzepatide carries an FDA boxed warning for thyroid C-cell tumors based on rodent carcinogenicity data. A 2024 systematic review of 10 RCTs covering 7,830 semaglutide-treated patients found thyroid cancer incidence below 1% and concluded no significant carcinogenic risk for semaglutide specifically. [9] Whether the rodent signal for the GLP-1 receptor agonist class translates to human risk remains genuinely unresolved, and the honest position is that we do not yet know.

Lean mass loss: The weight lost on tirzepatide is not purely fat. A 2024 clinical review in Nature Reviews Endocrinology identifies muscle mass loss accompanying substantial pharmacological weight reduction as a growing concern, particularly in older adults, with the long-term musculoskeletal consequences of that lean mass loss uncharacterized in any published long-term follow-up trial. [10] Patients and clinicians who focus exclusively on the scale number are missing part of the picture.

Practical Considerations

The cost picture for tirzepatide has shifted considerably since launch, and the compounding story is not settled.

List price: Tirzepatide (Zepbound) launched at approximately $1,060 per month for the 15 mg dose. Semaglutide 2.4 mg (Wegovy) runs approximately $1,350 per month before insurance. Neither figure reflects what most insured patients actually pay, and both are subject to manufacturer coupon programs that change frequently.

Dose escalation: Both tirzepatide and semaglutide 2.4 mg require 16 to 20 weeks of stepwise dose escalation before reaching maintenance, which affects how quickly a patient sees full efficacy. Liraglutide 3.0 mg reaches maintenance in 5 weeks but demands daily injection, a trade-off most patients find unfavorable.

Compounding: A 2024 Obesity Medicine Association FAQ and call-to-action document explicitly identifies regulatory uncertainty around compounded peptides as a persistent obstacle, calling on the FDA, pharmaceutical companies, compounding organizations, and health insurers to collaborate on clarity during shortage periods. [11] The FDA removed tirzepatide from the drug shortage list in 2024, creating genuine legal ambiguity for 503B outsourcing facilities that had been producing compounded versions. Patients sourcing compounded tirzepatide today are operating in a regulatory grey zone that may not persist.

The Scenarios Where Each Wins

These are not generic “consider patient preferences” recommendations. The evidence actually differentiates the agents.

Choose tirzepatide when:

• The patient has type 2 diabetes and obesity requiring both glycemic control and substantial weight reduction. A meta-analysis of RCTs found tirzepatide added to basal insulin provides weight loss exceeding that of GLP-1 receptor agonists in patients with uncontrolled type 2 diabetes, with the authors describing it as a meaningful advance for the “diabesity” population. [12]

• The primary goal is maximum fat loss and the patient has no established cardiovascular disease.

Choose semaglutide 2.4 mg when:

• The patient has established cardiovascular disease or high cardiovascular risk. A meta-analysis of 11 cardiovascular outcome trials covering 91,490 patients found GLP-1 receptor agonists reduced MACE versus placebo with a hazard ratio of 0.86 (95% CI 0.81-0.92), a roughly 14% relative risk reduction, and tirzepatide has no comparable outcomes dataset in obesity yet. [13] For a patient who has already had a myocardial infarction, that asymmetry in the evidence base is not a minor footnote.

Choose liraglutide 3.0 mg when:

• The patient cannot tolerate weekly injections for any reason, or requires a more gradual titration schedule than either weekly agent offers. The efficacy trade-off is real and substantial, but for some patients the dosing logistics of weekly agents are a genuine barrier.

Bottom Line

Tirzepatide produces the largest weight loss of any approved pharmacotherapy in phase 3 trials to date. For a patient whose primary goal is maximum fat reduction and who does not carry established cardiovascular disease, it is the current standard of care, and the evidence supporting that position is strong.

The absence of a published cardiovascular outcomes trial for tirzepatide in obesity is a genuine evidence gap, not a minor caveat. A meta-analysis of GLP-1 receptor agonist outcome trials found a 14% relative reduction in MACE across 91,490 patients for the class, and semaglutide has specific data in non-diabetic obese populations that tirzepatide simply does not yet have. [13] Clinicians managing patients with high cardiovascular risk should weight that gap heavily against the superior weight loss numbers, because “more weight lost” and “lower risk of dying from a cardiac event” are not interchangeable outcomes. The trial to answer this question for tirzepatide is running, and when those data arrive they will either close the gap or confirm that semaglutide holds a durable advantage for the highest-risk patients.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.

References

1. Weight loss efficiency and safety of tirzepatide: A Systematic review.. PloS one, 2023.

2. Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesity.. ESC heart failure, 2026.

3. Glucose-dependent insulinotropic polypeptide (GIP).. Molecular metabolism, 2025.

4. Transforming obesity: The advancement of multi-receptor drugs.. Cell, 2024.

5. Clinical Pharmacokinetics of Semaglutide: A Systematic Review.. Drug design, development and therapy, 2024.

6. Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.. Endocrinology, diabetes & metabolism, 2026.

7. Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.. Endocrine, 2024.

8. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.. Nature medicine, 2026.

9. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.. International journal of molecular sciences, 2024.

10. Sarcopenic obesity in older adults: a clinical overview.. Nature reviews. Endocrinology, 2024.

11. Frequently asked questions to the 2023 obesity medicine association position statement on compounded peptides: A call for action.. Obesity pillars, 2024.

12. Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.. Frontiers in endocrinology, 2022.

13. The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis.. Cardiovascular diabetology. Endocrinology reports, 2026.